High-throughput framework for genetic analyses of adverse drug reactions using electronic health records
Open Access
- 1 June 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (6) , e1009593
Abstract
Understanding the contribution of genetic variation to drug response can improve the delivery of precision medicine. However, genome-wide association studies (GWAS) for drug response are uncommon and are often hindered by small sample sizes. We present a high-throughput framework to efficiently identify eligible patients for genetic studies of adverse drug reactions (ADRs) using “drug allergy” labels from electronic health records (EHRs). As a proof-of-concept, we conducted GWAS for ADRs to 14 common drug/drug groups with 81,739 individuals from Vanderbilt University Medical Center’s BioVU DNA Biobank. We identified 7 genetic loci associated with ADRs at P < 5 × 10−8, including known genetic associations such as CYP2D6 and OPRM1 for CYP2D6-metabolized opioid ADR. Additional expression quantitative trait loci and phenome-wide association analyses added evidence to the observed associations. Our high-throughput framework is both scalable and portable, enabling impactful pharmacogenomic research to improve precision medicine.Keywords
Funding Information
- National Institutes of Health (R01 HL133786)
- National Institutes of Health (R35 GM131770)
- National Institutes of Health (P50 GM115305)
- National Institutes of Health (P50 GM115305)
- National Institutes of Health (P50 GM115305)
- National Institutes of Health (R01 HG010863)
- National Institutes of Health (R01 AR073764)
- U.S. Department of Veterans Affairs (1I01CX001741)
- National Center for Advancing Translational Sciences (2UL1 TR000445-06)
This publication has 39 references indexed in Scilit:
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- LocusZoom: regional visualization of genome-wide association scan resultsBioinformatics, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associationsBioinformatics, 2010
- The Value of CYP2D6 and OPRM1 Pharmacogenetic Testing for Opioid TherapyClinics In Laboratory Medicine, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT genePain, 2007
- Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationThe Pharmacogenomics Journal, 2006
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective StudiesSurvey of Anesthesiology, 1999